Skip to main content
OpenTrials

Clinical trial condition

HER2-Positive Metastatic Breast Cancer

Explore clinical trials studying HER2-Positive Metastatic Breast Cancer. Study availability and eligibility vary by location and protocol.

19 public trials 8 recruiting studies
Refine in advanced search Browse all conditions

HER2-Positive Metastatic Breast Cancer trial results

Active, not recruiting

Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.

NCT05230810

Conditions
HER2-Positive Metastatic Breast Cancer
Locations
  • University of Colorado Cancer Center Aurora, Colorado, United States
  • Cancer Care & Hematology-Fort Collins Fort Collins, Colorado, United States
  • Louisiana State University Health Sciences Center New Orleans, Louisiana, United States
  • University of Wisconsin Carbone Cancer Center Madison, Wisconsin, United States
View Trial Details
Active, not recruiting

ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

NCT05650879

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +11 more
Locations
  • University of Colorado - Anschutz Medical Campus - PPDS Aurora, Colorado, United States
  • Advent Health Orlando Orlando, Florida, United States
  • BRCR Medical Center Inc Plantation, Florida, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
View all 39 locations
View Trial Details
Completed

Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer

NCT02605915

Conditions
Breast Diseases, Breast Neoplasms, HER2-Positive Metastatic Breast Cancer, +6 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • University of Arkansas for Medical Sciences; Winthrop Rockefeller Cancer Institute Little Rock, Arkansas, United States
  • Joliet oncology hematology associates Joliet, Illinois, United States
  • Horizon Oncology Research, Inc. Lafayette, Indiana, United States
View all 20 locations
View Trial Details
Terminated

Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors

NCT06714617

Conditions
Adnexal Diseases, Breast Cancer Stage III, Breast Diseases, +48 more
Locations
  • SCRI-Denver HealthOne Denver, Colorado, United States
  • Yale Cancer Center New Haven, Connecticut, United States
  • SCRI-Florida Cancer Center Specialists Lake Mary Lake Mary, Florida, United States
  • Hematology Oncology Associates of the Treasure Cost Port Saint Lucie, Florida, United States
View Trial Details
Terminated

HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer

NCT06595563

Conditions
HER2-Positive Metastatic Breast Cancer, HER2-positive Advanced Breast Cancer
Locations
  • Institut Jules Bordet Anderlecht, Brussels Capital, Belgium
  • CHU Charleroi - Marie Curie Charleroi, Belgium
  • UZ Gent Ghent, Belgium
  • UZ Leuven Leuven, Belgium
View Trial Details

Related conditions